General contact

E-mail Novartis Pharmaceuticals

1-888-NOW-NOVA (1-888-669-6682)
Monday - Friday, 8:30am - 5:00pm EST
In case of Medical Emergency, please contact your Physician immediately.

Customer Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
Please allow for mail processing and postal service turnaround time



US Pharma Media Relations

For reporters only. Consumers will be directed to

Anna Frable, Vice President
Novartis Pharmaceutical Corporation Communications

icon-phone.gif+1 862 778 5388 (for reporters only)
icon-fax.gif+1 732 673 5262


More Information


Novartis Patient Assistance

This program is for U.S. Residents only.

Monday - Friday, 8:30am - 5:00pm EST

Novartis Patient Assistance Program
PO Box 66556
St. Louis, MO 63166-6556

More Information


Safe Harbor Privacy Statement

Safe Harbor Standards

This Safe Harbor Privacy Statement (the "Statement") sets forth the privacy principles followed by Novartis Pharmaceuticals Corporation (Novartis) in connection with the transfer and protection of "personal information" received from the European Union (EU) or Switzerland.

About The Safe Harbor

The Safe Harbor program is a voluntary self-certification process for companies operating in the United States. Companies that certify represent that they are upholding privacy standards for personal information received from the EU and Switzerland that have been jointly accepted by the EU Commission, the Swiss Federal Data Protection and Information Commissioner and the US Department of Commerce. These standards exceed current US privacy standards. Novartis has certified to the Safe Harbor program and makes that commitment.

"Personal Information" means information that can directly or indirectly lead to the identification of a living person, such as an individual's name, address, e-mail, telephone number, license number, medical identification number, photograph, or other identifying characteristic. The identification can occur by reference to one or more factors specific to the individual's physical, physiological, mental, economic, cultural or social identity. Personal information does not include information that has been anonymized, encoded or otherwise stripped of its identifiers, or information that is publicly available, unless combined with other non-public personal information.


This Statement governs personal information transferred from countries in the EU or from Switzerland (which has adopted substantially similar privacy laws to those of the EU), to the United States on behalf of Novartis. It applies to personal information in electronic and off-line formats.

Safe Harbor Privacy Principles

The following privacy principles apply to the transfer, collection, use or disclosure of personal information from the EU and Switzerland by Novartis.

Notice: Novartis informs individuals in the EU and Switzerland about the purposes for which it collects and uses their personal information, how to contact Novartis, the types of third parties with which Novartis shares their personal information, and the choice and means Novartis offers for limiting the use and disclosure of their personal information.

Consistent with the Safe Harbor requirements, Novartis may not be in a position to furnish notice in certain limited situations. Specifically, notice is not required where the processing of EU or Swiss personal information is necessary to respond to a government inquiry; is required by applicable laws, court orders or government regulations; or is necessary to protect Novartis' legal interests and providing notice would interfere with those interests.

Choice: Novartis will not process personal information about EU or Swiss individuals for purposes other than those for which the information was originally obtained or subsequently authorized by the EU or Swiss individual unless the individual affirmatively and explicitly consents ("opt-in") to the processing, or unless an exception applies. Novartis also provides EU and Swiss individuals with the opportunity to withdraw consent at any time ("opt-out"), in which case their personal information will not be further processed. There are certain limitations on the right to opt-out, such as those that apply in the clinical research situation. In that situation, Novartis can continue to rely upon personal information already provided by clinical research participants who choose to discontinue participation in a clinical trial, to the extent needed to protect the integrity of the study, but cannot collect any additional personal information about that individual once the written request to withdraw participation is received.

Data Integrity: Novartis seeks to ensure that any personal information held about EU and Swiss individuals is accurate, complete, current and otherwise reliable in relation to the purposes for which the information was obtained. Novartis collects personal information that is adequate, relevant and not excessive for the purposes for which it is to be processed. EU and Swiss individuals have a responsibility to assist Novartis in maintaining accurate, complete and current personal information about them.

Transfers To Third Parties: Novartis will only transfer personal information about EU and Swiss individuals to third-parties where the third-party (a) has provided satisfactory assurances to Novartis that it will protect the information consistently with this Statement; or (b) is located in the EU, Switzerland or a country considered "adequate" for privacy by the EU Commission and the Swiss Federal Data Protection Commissioner, and therefore is required to comply with the EU and Swiss data protection laws or substantially equivalent privacy laws; or (c) the third-party has also certified to the Safe Harbor, and is accordingly independently responsible for complying with the Safe Harbor requirements.

Where Novartis has knowledge that a third-party to whom it has provided EU or Swiss personal information is processing that information in a manner contrary to this Statement or the Safe Harbor requirements, Novartis will take reasonable steps to prevent or stop the processing.

Access And Correction: Upon written request to Novartis Pharmaceuticals Corporation, Novartis will provide EU and Swiss individuals with reasonable access to their personal information. Novartis will also take reasonable steps to allow EU and Swiss individuals to review their information for the purposes of correcting their information. There are certain limitations to the Access and Correction rights, as set forth in the US Department of Commerce's Safe Harbor website.

Security: Novartis takes reasonable precautions to protect EU and Swiss personal information in its possession from loss, misuse, unauthorized access, disclosure, alteration and destruction.

Enforcement: Novartis has established internal mechanisms to verify its ongoing adherence to this Statement. Novartis also encourages individuals covered by this Statement to raise any concerns about our processing of their personal information by contacting Novartis' Privacy Office at the address below or by contacting their local privacy officer or Legal Department. Novartis will seek to resolve any concerns. Novartis has also agreed to participate in the dispute resolution program provided by the European Data Protection Authorities and the Swiss Federal Data Protection Commissioner.

Limitation On Scope Of Principles: Adherence to these Privacy Principles may be limited to the extent required to meet a legal, governmental, national security or public interest obligation.

Contact Information: Questions or comments about this Statement should be directed to:

Novartis Privacy Office
1 Health Plaza
East Hanover, NJ, USA 07045